tbuckley/cabot-search huggingface dataset:
META-ANALYSIS ON EFFICACY OF CARDIAC CT ANGIOGRAPHY VERSUS TRANSESOPHAGEAL ECHOCARDIOGRAPHY FOR FOLLOW UP IN PATIENTS POST LEFT ATRIAL APPENDAGE CLOSURE
Authors: Sandeep Banga, Mohammed Osman, Sirish Shrestha, Abhiram Challa, Mina Mehanni, Irfan Zeb, Partho Sengupta, Sudarshan Balla, Madhavi Kadiyala, James Mills, Pratik Agrawal, Yasmin S. Hamirani
Journal: Journal of the American College of Cardiology (2020)
CLINICAL AND ECHOCARDIOGRAPHIC PROGNOSTIC MARKERS OF RIGHT VENTRICULAR FAILURE AFTER LEFT VENTRICULAR ASSIST DEVICE
Authors: Maria Karmpalioti, Yuko Soyama, Peter Huntjens, David Raymer, Shane LaRue, Akinobu Itoh, Phillip King, Joel Schilling, Justin Vader, John Gorcsan
Journal: Journal of the American College of Cardiology (2020)
Heuristics and the naturalistic fallacy
Authors: Christopher J. Kalbach
Journal: Behavioral and Brain Sciences (2020)

Abstract Lieder and Griffith's account of resource-rationality relies heavily on a notion of teleology. In this commentary, I criticize their teleocentric view as being incompatible with evolutionary theory, in which they aim to ground their analysis. As such, to save their view, I argue that they must jettison the notion of teleology, and their teleologically laden conclusions.
Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors
Authors: William L. Border, Ritu Sachdeva, Kayla L. Stratton, Saro H. Armenian, Aarti Bhat, David E. Cox, Kasey J. Leger, Wendy M. Leisenring, Lillian R. Meacham, Karim T. Sadak, Shanthi Sivanandam, Paul C. Nathan, Eric J. Chow
Journal: JACC CardioOncology (2020)

Childhood cancer survivors undergo serial echocardiograms to screen for cardiotoxicity. It is not clear whether small longitudinal changes in functional or structural parameters over time have clinical significance.To assess the timing of changes in serial echocardiographic parameters in pediatric age childhood cancer survivors and to evaluate their associations with cardiomyopathy development.We performed a multi-center retrospective case-control study of ≥1-year survivors following the end of cancer therapy. Cardiomyopathy cases (fractional shortening (FS) ≤28% or ejection fraction (EF) ≤50% on ≥2 occasions) were matched to controls (FS ≥30%, EF ≥55%, not on cardiac medications) by cumulative anthracycline and chest radiation dose, follow-up duration, and age at diagnosis. Digitally archived clinical surveillance echocardiograms were quantified in a central core lab, blinded to patient characteristics. Using mixed models with interaction terms between time and case status, we estimated the least square mean differences of 2D, M-mode, pulsed wave Doppler and tissue Doppler imaging derived parameters across time between cases and controls.We identified 50 matched case-control pairs from 5 centers. Analysis of 412 echocardiograms (cases, n=181; controls, n=231) determined that indices of LV systolic function (FS, biplane EF), diastolic function (mitral E/A ratio), and LV size (end diastolic dimension z-scores) were significantly different between cases and controls, even four years prior to the development of cardiomyopathy.Longitudinal changes in cardiac functional parameters can occur relatively early in pediatric age childhood cancer survivors and are associated with the development of cardiomyopathy.
Use of STAT3 polymorphisms to predict overall survival in patients treated with interferon-alpha for metastatic renal cell carcinoma.
Authors: Masatoshi Eto, Tomomi Kamba, Hideaki Miyake, Masato Fujisawa, Takao Kamai, Hirotsugu Uemura, Taiji Tsukamoto, Haruhito Azuma, Akio Matsubara, Kazuo Nishimura, Tsuyoshi Nakamura, Osamu Ogawa, Seiji Naito
Journal: Journal of Clinical Oncology (2012)

e15048 Background: We previously reported that the single nucleotide polymorphisms (SNPs) in signal transducer and activator 3 (STAT3) gene were most significantly associated with better response to interferon (IFN)-α in patients with metastatic renal cell carcinoma (mRCC) in our retrospective analysis (JCO 25:2785, 2007). We conducted this trial to prospectively confirm the results, and reported the significant association between the SNPs of STAT3-2 and clinical benefits (CR, PR, and SD more than 24 weeks) of IFN-α (p = 0.039) (ASCO 2011, abstract No. 4590). In this study, we have further analyzed the correlation between overall survival (OS), progression-free survival (PFS) and the 11 SNPs reported previously. Methods: In this multicenter, prospective study, patients with histologically confirmed RCC that was metastatic, measurable disease, age &gt; 20 years, ECOG PS 0-1 and adequate organ function received 3 dosages of 5 million U per week of IFN-α treatment. We evaluated the correlation between OS, PFS and SNP allele frequencies of STAT3-2, STAT3-0, SOCS3-1, IL4R-34, PTGS1-3, PTGS1-4, PTGS1-5, PTGS2-12, IRF2-67, ICSBP-38, and TAP2-5 (JCO 25:2785, 2007) in mRCC patients treated with IFN-α. Association between OS, PFS and genetic polymorphisms was analyzed using Logrank test for trend. Results: Two hundreds three eligible patients were enrolled between December 2006 and October 2009. All patients had prior nephrectomy, and 88.7% had ECOG PS 0. Ninety-four percent of patients had clear cell RCC, and 5% had papillary RCC. At the time of this analysis the central review assessed response rate was 13.8% (28/203) (9 CR, 19 PR). CR rate of 4.4% (9/203) was more than we expected. PFS was not associated with any of the 11 SNPs examined. However, 2 SNPs of STAT3 gene, STAT3-2 and STAT3-0, were significantly associated with OS, and the correlation of STAT3-2 (p = 0.0347) was stronger than that of STAT3-0. Namely, C/C genotype of STAT3-2 was significantly associated with prolonged OS compared with the other genotypes (C/T and T/T). Conclusions: This is the first prospective study demonstrating that STAT3 polymorphisms can predict OS in mRCC patients treated with IFN-α.
Clinical significance of <i>BIM</i> deletion polymorphism in non-small cell lung cancer with epidermal growth factor receptor mutation.
Authors: Kazutoshi Isobe, Yoshinobu Hata, Kyohei Kaburaki, Hiroshi Kobayashi, Keishi Sugino, Susumu Sakamoto, Naobumi Tochigi, Yujiro Takai, Kazutoshi Shibuya, Keigo Takagi, Sakae Homma
Journal: Journal of Clinical Oncology (2013)

11052 Background: Germ line alterations in the proapoptotic protein BCL2-like 11 (BIM) can have a crucial role in how a tumor responds to treatment. To clarify the clinical usefulness of detecting BIM deletion polymorphism in non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) mutation we examined the prognosis in patients with or without the BIM changes. Methods: Seventy NSCLC patients with positive EGFR mutation treated with EGFR-tyrosine kinase inhibitor (EGFR-TKI) between January 2008 and January 2013 were enrolled in this study. BIM deletion polymorphism was analyzed by PCR in 58 peripheral blood samples, 24 formalin-fixed paraffin-embedded (FFPE) slides of surgical specimens (lung tissue in 20, brain tissue in 4), and 12 samples that included both blood and tissue specimens. We performed retrospective analyses on clinical characteristics, response rate and toxicity of EGFR-TKI, and estimated the prognosis in patients with or without BIM deletion polymorphism. Results: BIM deletion polymorphism was present in 13 of 70 patients (18.6%) with homozygous deletion in 1 and heterozygous deletion in 12. There was no discordance between the two types of samples among the 12 patients. There were no significant differences between patients with or without BIM deletion polymorphism on clinical characteristics, response rate to EGFR-TKI and incidence of EGFR-TKI toxicity. Patients with BIM deletion polymorphism showed significantly shorter PFS that in patients without BIM deletion polymorphism (median: 216 days vs. 430 days, p &lt; 0.001). There was no significant difference in OS. In multivariate analyses using the Cox regression model, BIM deletion polymorphism (hazard ratio = 4.2, p&lt; 0.001, 95% CI = 2.026-8.777) was identified as an independent factor for shorter PFS. Conclusions: BIM deletion polymorphism could be detected by PCR on peripheral blood samples and FFPE slides of surgical specimens. BIM deletion polymorphism has emerged as an independent prognostic factor for shorter PFS. Therefore, new treatment strategies should be established for patients with BIM deletion polymorphism.
ANTITHROMBOTIC TREATMENT PATTERN IN NEWLY DIAGNOSED ATRIAL FIBRILLATION PATIENTS AND 2-YEAR FOLLOW-UP RESULTS FOR DABIGATRAN-TREATED PATIENTS IN THE AFRICA/MIDDLE EASTERN REGION: PHASE II RESULTS FROM THE GLORIA-AF REGISTRY PROGRAM
Authors: Rabih R. Azar, Hany Ragy, Omer Kozan, Maurice EL Khuri, Nooshin Bazergani, Dongmei Zhai, Christine Teutsch, Mohamed Ibrahim, Gregory Y.H. Lip, Menno Huisman
Journal: Journal of the American College of Cardiology (2020)
ADDITIVE EFFECT OF MULTIPLE HIGH BLEEDING RISK CRITERIA IN PATIENTS UNDERGOING PCI
Authors: Davide Cao, Roxana Mehran, George D. Dangas, Rishi Chandiramani, Samantha Sartori, Anastasios Roumeliotis, Ridhima Goel, Johny Nicolas, Usman Baber, Giulio G. Stefanini, Jason Kovacic, Joseph Sweeny, Prakash Krishnan, Nitin Barman, Samin K. Sharma, Annapoorna Subhash Kini
Journal: Journal of the American College of Cardiology (2020)
Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.
Authors: Senem Karabulut, Leyla Kilic, Rumeysa Ciftci, Ibrahim Yildiz, Fatma Sen, Serkan Keskin, Didem Tastekin, Faruk Tas
Journal: Journal of Clinical Oncology (2013)

e11592 Background: Activated coagulation and fibrinolytic system in cancer patients is associated with tumor stroma formation and metastasis in different cancer types. The aim of this study is to explore the correlation of blood coagulation tests for various clinicopathologic factors in breast cancer patients. Methods: The study involves treatment-naive female breast cancer patients. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), prothrombin activity (PTA), INR, D-dimer, fibrinogen levels and platelet counts were evaluated. Results: Between February 2010 and June 2011, 123 consecutive female patients with breast cancer were enrolled into the study. Median age of diagnosis was 51 years old (range: 26-82). 22 % of the group consisted of metastatic breast cancer patients. The plasma level of all coagulation factors revealed statistically significant difference between patient and control group except for PT (p&lt;0.001 for all variables except for PT; p=0.08). Elderly age (&gt;50 years) was associated with higher D-dimer levels (median 174 vs 345 U/ml, p=0.003). Metastatic patients exhibited significantly higher D-dimer values when compared with early breast cancer patients (median 205 U/ml vs 407.2 U/ml, p=0.049). Advanced tumor stage (T3&amp;T4 vs T1&amp;T2) was associated with higher INR (median 1.15 vs 1.09, p=0.05) and lower prothrombin activity (median: 82 % vs 70 %, p=0.025). Conclusions: Plasma D-dimer levels are elevated among metastatic breast cancer patients. Involvement of axillary lymph nodes and hormone receptor status does not seem to have an effect on coagulation parameters. For daily practice, D-dimer may be a suitable test for evaluation of disease extent before designing treatment strategy.
Abstract 13179: New Insights Into Right Ventricular Performance During Exercise Using High-Fidelity Conductance Catheters to Generate Pressure Volume Loops
Authors: CornwellWilliam K, Greg Coe, Amrut Ambardekar, Jay Pal, Christine Tompkins, Matthew Zipse, Gene Wolfel, Andreas Brieke, Benjamin Levine, Wendy Kohrt
Journal: Circulation (2018)

Introduction: Despite a growing interest in right ventricular (RV) function in health and disease, RV performance has not been extensively characterized. Therefore, we prospectively assessed RV fun...
Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8<sup>+</sup>T-cell functionality
Authors: Seyedeh-Raheleh Niavarani, Christine Lawson, Marie Boudaud, Camille Simard, Lee-Hwa Tai
Journal: Journal for ImmunoTherapy of Cancer (2020)

The occurrence of triple-negative breast cancer (TNBC) is significant, with an estimated 40,000 cases diagnosed in US women each year (American Cancer Society, 2018). TNBC is a vastly heterogeneous disease that are grouped together histologically since they lack hormone and Her-2 receptors. However
Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study.
Authors: Charles L. Loprinzi, Rui Qin, Shaker R. Dakhil, Louis Fehrenbacher, Philip J. Stella, Pamela J. Atherton, Drew K. Seisler, Rubina Qamar, Grant Carlton Lewis, Axel Grothey
Journal: Journal of Clinical Oncology (2013)

3501 Background: Cumulative neurotoxicity commonly leads to early discontinuation of oxaliplatin-based therapy. In a relatively small, prematurely-discontinued, randomized study, IV CaMg was associated with reduced oxaliplatin-induced sNT (Grothey, JCO, 2011). N08CB was designed to definitively test whether IV CaMg significantly decreases cumulative oxaliplatin-related sNT. Methods: 353 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to 3 arms: IV CaMg (1g calcium gluconate, 1g magnesium sulfate) before and after oxaliplatin vs PL before and after vs CaMg before and PL after. The primary endpoint was cumulative sNT repeatedly measured by the sensory subscale of the EORTC QLQ-CIPN20. Secondary endpoints, using CTCAE 4.0 and an oxaliplatin specific neurotoxicity scale, were also assessed. Acute neuropathy data were also collected for 5 days following each oxaliplatin dose. The area under the curve (AUC) of the sensory subscale during the treatment cycles was used as summary measures for comparison. The Wilcoxon rank-sum tests were conducted for each treatment versus placebo arm, at 2.5%, adjusting for multiplicity using Bonferroni’s approach. Results: CaMg did not reduce cumulative sNT. Primary and secondary analyses data are summarized in the Table. In addition, there were no significant differences between arms regarding oxaliplatin administered doses or chemotherapy discontinuation rates. Also, there were no substantial differences in acute neuropathy scores or side-effects between study arms. Conclusions: This study does not demonstrate any activity of IV CaMg as a neuroprotectant against oxaliplatin-induced neurotoxicity. Clinical trial information: NCT01099449. [Table: see text]
Outcomes associated with retinoblastoma and c-myc gene expression in patients with testicular cancer: A ten-year experience
Authors: H. Astudillo-De La Vega, E. Ruiz-Garcia, M. Salcedo, A. Torres, J. A. De La Cruz, A. Benitez, P. Gariglio, F. Gutierrez-Delgado
Journal: Journal of Clinical Oncology (2006)

14656 Purpose: To determine and correlate the protein and mRNA expression of c-myc and Rb genes in normal testicular tissue and testicular cancer as possible markers of pharmacological response. Methods: Eleven fresh testicular cancer surgical specimens were obtained from untreated patients with histological diagnosis of seminoma (9/11) and non seminoma (2/11) during the period of 1992 to 1995. Age patient average was 35 (16–74). Two normal human testicular tissues also were evaluated as control. Single and double immunohistochemical assay was performed with peroxidase anti-peroxidase system using polyclonal antibody anti-pRb C-15 and monoclonal antibody anti- c-myc 1. Non radioactive in situ hybridization with cRNA probes was performed with cDNA from Rb (exons 2–27) and c-myc (exons 2,3). All seminomas were stage I and were treated with radiotherapy. Non-seminomas were stage III and were treated with chemotherapy. Results: Histological findings: Rb protein was expressed in mature cells toward the lumen of normal testicular tissue while c-myc was located in basal cells but decreasing the expression toward the lumen. High correlation between mRNA and protein levels for both genes was observed in normal testicular tissue. Rb protein and mRNA was absent in 6/11 (55%) tumors while the remaining showed a low level expression (45%). A high c-myc expression was observed in 6/11 (55%) seminomas specimens correlating in a few cases with absent Rb expression. Percentage of positive cells to c-myc gene expression (mRNA and protein) was highly increased in tumoral samples. Clinical findings: All patients with seminoma (9/11) and one of non seminoma (1/11) are alive and without tumoral activity a ten years of the diagnosis. A non-seminoma patient (1/11) have 11-year survival, a high expression of c-myc gene and absent retinoblastoma expression was observed in this case. Conclusion: The semiquantitative differences observed on c-myc and Rb gene expression in seminoma and non-seminoma tumors might correlate with the biological behavior including their high proliferation rate and the chemosensitivity. No significant financial relationships to disclose.
Dementia: A Personal Story
Authors: Gerald S. Lazarus
Journal: Annals of Internal Medicine (2020)

On Being a Doctor17 March 2020Dementia: A Personal StoryGerald S. Lazarus, MDGerald S. Lazarus, MDDuke University School of Medicine, Durham, North Carolina (G.S.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-2766 Audio Reading - “Dementia: A Personal Story” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Dementia: A Personal Story” by Gerald S. Lazarus, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I am now a full-time physician–caregiver. It took 3 years to determine whether my wife's behavioral changes were willful or a result of dementia. Today, after the clinical diagnosis of “dementia” is made, exact diagnosis still requires brain tissue to characterize the specific type of dementia. The only proven interventions to minimally slow dementia are a good diet, exercise, and mental engagement. The physician–caregiver must otherwise helplessly watch the slow deterioration of a family member, partner, or friend.It took me almost 2 years after my wife's diagnosis to emotionally internalize that she had a terminal neurologic disease and that ... Author, Article, and Disclosure InformationAffiliations: Duke University School of Medicine, Durham, North Carolina (G.S.L.)Corresponding Author: Gerald S. Lazarus, MD, 2701 Pickett Road, 67 Forest at Duke Drive, Durham, NC 27705; e-mail, gerald.[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Dementia: A Personal Story” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Dementia: A Personal Story” by Gerald S. Lazarus, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 March 2020Volume 172, Issue 6Page: 433-434KeywordsBrainCaregiversDementiaEmotionsMemoryProteinsPsychometricsQuality of lifeVisionWheelchairs ePublished: 17 March 2020 Issue Published: 17 March 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Association of tumor perivascular desmin expression with survival in patients with sunitinib-treated renal carcinoma.
Authors: Magnus Frodin Bolling, Per Sandström, Artur Mezheyeuski, Lars Egevad, Arne Ostman
Journal: Journal of Clinical Oncology (2013)

11097 Background: The introduction of tyrosine kinase inhibitors has markedly improved the outcome for patients with metastatic renal carcinoma (mRCC), but lack of reliable response-predictive markers makes it difficult to individualize treatment. Pericytes surround endothelial cells of capillaries and regulate vessel function. Associations between pericyte marker expression and response to sunitinib have not been well characterized. Methods: A tissue micro array with samples from 67 mRCC patients ( 34 males, 33 females, age 42 – 84) treated at Dept. of Oncology, Karolinska University Hospital where constructed from primary tumors. All patients included had received at least one course with the tyrosine kinase receptor inhibitor sunitinib. Data of treatment, progression free survival and overall survival was collected in a clinical registry. Tissues were double-stained with the endothelial cell marker CD 34 and either of three pericyte markers desmin, PDGF beta receptor and alpha smoth muscle actin (ASMA). By semi-quantitative visual scoring, the perivascular staining of these markers was evaluated and cases dichotomized into negative/low- or positive/high-expressing groups. Results: For patients with desmin positive/high vessels ( n = 12), median PFS where 5.0 months (2.9 – 7.1, 95% CI) vs 7.0 months for patients with desmin negative/low vessels (n = 55, 3.8 – 10.2, 95% CI, Mantel Cox log rank test p&lt;0.02). The median OS in the desmin-positive/high group was 24 months ( 7 – 41, 95% CI) vs 46 months in the negative/low group ( 34 – 58, 95 % CI, Mantel Cox log rank test p&lt;0.014). No significant associations were seen between PFS or OS and the expression of perivascular PDGF beta receptor or ASMA. Conclusions: Metastatic RCC displays a clinically relevant variation in perivascular desmin expression which is associated with survival in sunitinib-treated patients. Future studies are warranted which further explores the prognostic and/or response-predicative capacity of this novel candidate renal cell cancer biomarker.
Abstract 13353: Ketogenesis Protects Mitochondrial Function by Modulating Post-Translational Modification
Authors: Yuichiro Arima, Toshifumi Ishida, Taishi Nakamura, Satoshi Araki, Eiichiro Yamamoto, Kenji Sakamoto, Koichi Kaikita, Kenichi Tsujita
Journal: Circulation (2019)

Introduction: Ketone body metabolism functions as an emergent energy server in the starvated condition. Recent findings illuminated beneficial roles of ketone bodies for health and disease. However...
Three-Year Follow-up on Safety and Effectiveness of Rituximab Plus Chemotherapy As First-Line Treatment of Diffuse Large B-Cell Lymphoma
Authors: Jifeng Feng, Jianqiu Wu, Yongping Song, Liping Su, Mingzhi Zhang, Wei Li, Yu Hu, Xiaohong Zhang, Yuhuan Gao, Zuoxing Niu, Ru Feng, Wei Wang, Jiewen Peng, Xiaolin Li, Xuenong Ouyang, Changping Wu, Weijing Zhang, Yun Zeng, Zhen Xiao, Yingmin Liang, Yongzhi Zhuang, Jishi Wang, Zimin Sun, Hai Bai, Tongjian Cui
Journal: Blood (2017)